What it is
MOTS-c is a peptide 16 amino acids long that the human body makes for itself.
What makes it genuinely unusual is where the instructions for it are kept. Nearly every protein in a human body is written in the DNA inside the cell nucleus. MOTS-c is not. It is encoded inside mitochondrial DNA — the small separate genome carried by mitochondria, the compartments that produce most of a cell's usable energy — in a short readable stretch tucked within the gene for the 12S ribosomal RNA.
That is what the name records. MOTS-c stands for mitochondrial open reading frame of the 12S rRNA-c: an address, not a description of what it does.
The idea behind it is worth stating plainly, because it is the reason the compound attracted attention at all. Mitochondria were long understood as the cell's power plants. Finding that they also encode signalling peptides suggests they talk to the rest of the body as well as fuelling it.
What it is said to be good for
Insulin sensitivity, fat metabolism, exercise capacity and ageing.
Those claims are not invented. They trace directly to a real and heavily cited paper — and to a set of mice.
What the research shows
The founding result is a mouse result. Lee and colleagues reported MOTS-c in Cell Metabolism on 2015-03-03. In that paper, MOTS-c treatment in mice prevented age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity. The mechanism they described runs through skeletal muscle: MOTS-c inhibits the folate cycle and the purine synthesis tethered to it, which activates AMPK, a central energy sensor inside cells.
That is a striking finding, honestly reported by its authors as what it is. Everything sold under the name today rests on it.
The human literature is large, and it is not what it looks like. PubMed indexed 253 records for MOTS-c on 2026-09-07, of which 142 are tagged as human research. Fifty-six per cent human sounds like a compound with a serious clinical base.
Read the studies and the pattern is unmistakable. Human MOTS-c research almost entirely measures the peptide people already have rather than giving them any:
- A 2021 study in the Journal of Applied Physiology randomised volunteers to a session of endurance cycling or of resistance exercise and measured circulating mitochondrial-derived peptides, reporting that acute endurance exercise stimulates their levels in humans.
- Other work measures circulating MOTS-c in breast cancer patients taking metformin, in cancer survivors doing aerobic and resistance training, and across diabetes and kidney disease.
This is the distinction a beginner most needs, and the one vendor pages most reliably blur. Measuring a molecule in people is not testing it in people. A study showing that your MOTS-c goes up after a bike ride tells you something interesting about exercise physiology. It tells you nothing about what happens if MOTS-c is injected instead of earned.
Administration in humans is, as of tonight, almost untested. ClinicalTrials.gov lists five interventional studies naming MOTS-c. Most are studies of something else that measure MOTS-c as an outcome — an anesthesia comparison, a trial of GLP-1 and SGLT2 drugs, a diabetes cohort. One is filed as testing the compound itself: NCT07505745, a Phase 2 study of MOTS-c for insulin sensitivity in adults with prediabetes, 120 planned participants.
Corrected 2026-09-08. An earlier version of this entry counted that registration as evidence that a trial was under way. It should not be. Its sponsor, Hudson Biotech, has filed eight ClinicalTrials.gov registrations in total (registry API, 2026-09-08): all list one facility and start dates inside a two-week window in February 2026, and together they cover MOTS-c, BPC-157, TB-500, GHK-Cu, Melanotan II, tesamorelin, tirzepatide and retatrutide. Two of them carry Eli Lilly's own protocol identifiers — a registry search for I8F-MC-GPHK returns Lilly's completed tirzepatide study NCT04184622 alongside Hudson Biotech's filing, and J1I-MC-GZBF returns Lilly's completed retatrutide study NCT04881760 alongside Hudson Biotech's. None of the eight has posted results. This entry therefore does not treat that registration as evidence that a trial programme is under way. Peptifact's MOTS-c dosage reference sets out the full table of eight and how to reproduce the two identifier searches. No completed trial of administered MOTS-c has reported results.
So the honest summary is a sentence with two halves that are rarely printed together: MOTS-c is one of the better-characterised molecules in this library as a piece of human biology, and one of the least tested as a treatment.
How this compares
The habit of reading a large human paper count as a large clinical evidence base is not unique to this compound. AICAR has 1,128 human-tagged records, a substantial share of them about the molecule the body makes itself in inherited metabolic disorders rather than about giving it to anyone.
Where it stands
Approved as a medicine: nowhere.
In development: nothing that survives checking. One registered Phase 2 trial exists on paper, from a sponsor whose eight filings do not withstand it; no completed administration trial has reported.
Available as: a research chemical.
Related entries in this library: humanin, the other mitochondrial-derived peptide, was the discovery that prompted the search that found MOTS-c — and its trial registry is the better cautionary tale, holding seven records of which not one administers the peptide. An approved analogue in the same broad class shows what the evidence looks like at the other end of the scale — an approved drug with a label, a trial base and a stated limitation. For a metabolic compound whose literature is dominated by drug-testing laboratories rather than by either, see the growth-hormone fragment 176-191. And for the measurement that insulin-sensitivity work actually rests on, see the 31-residue offcut released with every insulin molecule — the entry in this library with the largest literature and no market at all.
Last checked
2026-09-07. The PubMed counts and the ClinicalTrials.gov records were retrieved on that date through the NCBI E-utilities and the registry API; the 2015 and 2021 findings are quoted from the published abstracts named above.